Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 6:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 4,112 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Experimental 2 Clear all

Conditions: Non-small Cell Lung Cancer, Non-small Cell Lung Cancer Stage IV
Interventions: Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy; Drug · Radiation
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Insomnia, Suicidal Ideation, Suicide, Attempted
Interventions: TAILOR, Enhanced Usual Care; Behavioral · Other
Lead sponsor: Jeff Bridge; Other
Eligibility: 11 Years to 18 Years
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: IOV-2001, Low dose IL-2, High dose IL-2, IL-2; Biological · Drug
Lead sponsor: Iovance Biotherapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Tampa, Florida • Durham, North Carolina • Cincinnati, Ohio + 4 more

Conditions: Advanced Breast Cancer, Anxiety, CBD
Interventions: Cannabidiol, Placebo; Drug · Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: PHYSIOLOGICAL PHENOMENA, Homeostasis, Physical Functional Performance, Cardiorespiratory Fitness, Cardiometabolic Risk Factors, Mobility Limitation
Interventions: Standardized Physiologic Resilience Challenge, Multimodal Whole-Body Physiologic Monitoring, Research-Only Whole-Body Digital Twin Analysis; Procedure · Other
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2041
U.S. locations: 1
States / cities: New York, New York

Conditions: Hospital Readmission
Interventions: Automatic notification of readmissions; Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Amputation
Interventions: Experimental prosthetics foot (K3 Promoter); Device
Lead sponsor: Tensegrity Prosthetics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Arvada, Colorado

Conditions: Social Media, Digital Well-being
Interventions: Friction-Based Smartphone Intervention; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 24 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Preterm Birth
Interventions: Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo; Drug · Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Caffeine, Warfarin, Omeprazole, Metoprolol, Midazolam Hydrochloride; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Little Rock, Arkansas • Rogers, Arkansas • San Diego, California + 5 more

Conditions: Male Contraception, Semen Volume, Sperm Motility
Interventions: NLS-133, Placebo, Active Comparator #1; Drug
Lead sponsor: Next Life Sciences; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Granulomatous Disease (CGD), X-Linked Chronic Granulomatous Disease
Interventions: Campath, Sirolimus, Base-edited hematopoietic stem and progenitor cells, Busulfan, Palifermin, Filgrastim, Plerixafor; Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: Pemetrexed, Folic Acid, Vitamin B12; Drug · Dietary Supplement
Lead sponsor: Christopher Sweeney, MBBS; Other
Eligibility: 18 Years and older · Male only
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 15
States / cities: Galesburg, Illinois • Elkhart, Indiana • Fort Wayne, Indiana + 10 more

Conditions: Healthy
Interventions: Interprofessional Simulation Experience; Other
Lead sponsor: Youngstown State University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Youngstown, Ohio

Conditions: Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Treatment-Naive B Cell Malignancies
Interventions: TL-895, Navtemadlin; Drug
Lead sponsor: Telios Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 2
States / cities: Columbus, Ohio • Germantown, Tennessee

Conditions: Peripheral Arterial Disease, Intermittent Claudication, Peripheral Vascular Disease
Interventions: Magnetic Resonance Angiography; Other
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2018
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Metastatic Breast Cancer, HER2+ Breast Cancer
Interventions: BKM120, Trastuzumab, Capecitabine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 7
States / cities: Birmingham, Alabama • Fayetteville, Arkansas • Tampa, Florida + 4 more

Conditions: Improving Cardiometabolic Outcomes in Adults
Interventions: Melatonin 1 mg, Placebos, Meal Timing, NON Meal Timing; Dietary Supplement · Other
Lead sponsor: Northwestern University; Other
Eligibility: 35 Years to 54 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension (HTN), Hypertension
Interventions: Arugula Extract, Psyllium Husk; Dietary Supplement
Lead sponsor: Baylor University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Waco, Texas

Conditions: High Food Reinforcement, Overeating, Obesity, Childhood
Interventions: Triple P Parenting Videos, Activity Boxes; Behavioral
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 4 Years to 5 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Alcohol Drinking, Cigarette Smoking Toxicity
Interventions: Reduced nicotine cigarettes; Drug
Lead sponsor: Battelle Memorial Institute; Other
Eligibility: 21 Years to 65 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cigarette Smoking, Vaping
Interventions: Tobacco e-liquids, Menthol and Tobacco e-liquids, Mint, Menthol and Tobacco e-liquids, All e-liquid flavors; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Acute Myeloid Leukemia
Interventions: Quizartinib, Fludarabine, Cytarabine, Intrathecal (IT) triple chemotherapy prophylaxis, Etoposide; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 1 Month to 21 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 11
States / cities: Loma Linda, California • San Francisco, California • Aurora, Colorado + 8 more

Conditions: Motion Sickness
Interventions: Osteopathic Manipulative Treatment, Sham treatment; Other
Lead sponsor: United States Army Aeromedical Research Laboratory; Federal
Eligibility: 19 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Fort Rucker, Alabama

Search by objective public record fields.

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Targeting Adolescent Insomnia to Lessen Overall Risk of Suicidal Behavior

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

RCT of CBD for Anxiety in Advanced Breast Cancer

Truway Whole-Body Digital Twin and Physiologic Resilience Study (TRU-OMNIBODY)

Study of Physician Awareness of and Communication About Patient Readmissions to the Hospital

Stability and 3D Motion Study of an Experimental Prosthetic Foot

Digital Habit Interventions

Assessment of DHA On Reducing Early Preterm Birth

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

Effects of NLS-133, a Potential Non-Hormonal "On-Demand" Male Contraceptive

Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease

Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer

High-Fidelity Patient Simulation on Clinical Reasoning Skills and Interprofessional Competencies

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Non-Contrast Enhanced Peripheral Magnetic Resonance Angiography

Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

Strengthening Circadian Signals

Under Pressure: Arugula Extract's Effect on Blood Pressure in Hypertensive Individuals

The Play With Me Study

Reduced Nicotine Cigarettes in Smokers With and Without Alcohol Use Disorder

Menthol and Mint Experimental Tobacco Marketplace (ETM) Study

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Preliminary Evaluation of an Osteopathic Manipulative Treatment (OMT) to Prevent Motion Sickness Symptoms